{"id":"r-chop-r-dhap","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea/vomiting"},{"rate":null,"effect":"Infusion reactions (rituximab)"},{"rate":null,"effect":"Cardiotoxicity (doxorubicin)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rituximab targets CD20 antigen on B-cell lymphomas, enabling antibody-dependent cellular cytotoxicity and direct apoptosis. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and DHAP (dexamethasone, high-dose cytarabine, cisplatin) are cytotoxic chemotherapy regimens that damage DNA and disrupt cell division. The alternating schedule aims to overcome chemotherapy resistance in aggressive lymphomas.","oneSentence":"R-CHOP/R-DHAP is a combination chemotherapy regimen that uses rituximab (anti-CD20 monoclonal antibody) plus alternating cycles of CHOP and DHAP chemotherapy to kill lymphoma cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:31:05.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)"},{"name":"Mantle cell lymphoma"}]},"trialDetails":[{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT06482684","phase":"PHASE2","title":"CAR-T-cell Treatment for Untreated High Risk MANtle Cell Lymphoma","status":"RECRUITING","sponsor":"Christian Schmidt, MD","startDate":"2024-02-15","conditions":"Mantle Cell Lymphoma","enrollment":150},{"nctId":"NCT06255704","phase":"PHASE2","title":"A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2024-03-15","conditions":"Mantle Cell Lymphoma","enrollment":23},{"nctId":"NCT05429918","phase":"","title":"Ibrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle Cell Lymphoma Patients Who Aged ≤65 Years","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2020-12-30","conditions":"Mantle Cell Lymphoma","enrollment":60},{"nctId":"NCT02858258","phase":"PHASE3","title":"ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Prof. Dr. M. Dreyling (co-chairman)","startDate":"2016-07","conditions":"Mantle Cell Lymphoma","enrollment":870},{"nctId":"NCT00209222","phase":"PHASE3","title":"Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL","status":"UNKNOWN","sponsor":"European Mantle Cell Lymphoma Network","startDate":"2004-07","conditions":"Lymphoma, Mantle-Cell","enrollment":360},{"nctId":"NCT00283439","phase":"PHASE1, PHASE2","title":"A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-10","conditions":"Chemotherapy-Induced Thrombocytopenia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma","enrollment":39}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["rituximab, CHOP, DHAP"],"phase":"phase_3","status":"active","brandName":"R-CHOP/R-DHAP","genericName":"R-CHOP/R-DHAP","companyName":"Prof. Dr. M. Dreyling (co-chairman)","companyId":"prof-dr-m-dreyling-co-chairman","modality":"Small molecule","firstApprovalDate":"","aiSummary":"R-CHOP/R-DHAP is a combination chemotherapy regimen that uses rituximab (anti-CD20 monoclonal antibody) plus alternating cycles of CHOP and DHAP chemotherapy to kill lymphoma cells. Used for Relapsed or refractory diffuse large B-cell lymphoma (DLBCL), Mantle cell lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}